Clinical trials: Tumor Patients
Constipation
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
This study will evaluate the efficacy and safety of tegaserod in opioid-induced constipation in patients with non-cancer pain.
- Trial name
- NCT00365820
- Testing
- Tegaserod
- Where
- 59 sites in United States
- Volunteers
- 670 people
- Sponsor
- Novartis
Non-Hodgkin's Lymphoma
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous…
- Trial name
- NCT03075696
- Testing
- Glofitamab, Obinutuzumab, Tocilizumab
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 940 people
- Sponsor
- Hoffmann-La Roche
Leukemia
BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia
RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia that has not responded to treatment with cladribine.
- Trial name
- NCT00074048
- Testing
- BL22
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- MedImmune LLC
Advanced Cancer
Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors.
- Trial name
- NCT01863485
- Testing
- CM082 Tablet
- Where
- 3 sites in China
- Volunteers
- 44 people
- Sponsor
- AnewPharma
Ovarian Cancer, Non Small Cell Lung Cancer
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to estimate the rate of response for patients with ovarian, non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who are administered LY2523355.
- Conditions
- Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT01059643
- Testing
- LY2523355, pegfilgrastim
- Where
- 18 sites in United States
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This was a multi-center, open-label, Phase Ib dose escalation /Phase II study in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) patients considered to be resistant, ineligible or intolerant to…
- Trial name
- NCT01602315
- Testing
- BYL719 as film-coated (FC) whole tablets, BYL719 as dispersible tablets (DT), cetuximab
- Where
- 29 sites in United States, Australia and 7 more
- Volunteers
- 179 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
This study adopted a randomized, open-label, positive drug-controlled, multi-center trial design. The primary endpoint was PFS evaluated by the Independent Review Committee (IRC).
- Trial name
- NCT07008976
- Testing
- TQB2102 Injection, Trastuzumab Emtansine for Injection
- Where
- 31 sites in China
- Volunteers
- 246 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Ovarian Cancer, Cervical Cancer
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors
- Conditions
- Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT02988817
- Testing
- Enapotamab vedotin (HuMax-AXL-ADC)
- Where
- 41 sites in United States, Belgium and 4 more
- Volunteers
- 306 people
- Sponsor
- Genmab
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Inoperable or Recurrent Breast Cancer
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
To investigate of the clinical safety and effectiveness of eribulin mesylate in patients with inoperable or recurrent breast cancer
- Trial name
- NCT01463891
- Testing
- Eribulin Mesylate
- Where
- 223 sites in Japan
- Volunteers
- 963 people
- Sponsor
- Eisai Co., Ltd.
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.
- Trial name
- NCT02695290
- Testing
- Afatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
Metastatic Solid Tumors
Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors
The goal of this Phase Ib/II interventional study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of QLC5513 combined with QL1706± platinum in the treatment of patients with advanced or metastatic malignant…
- Trial name
- NCT07272590
- Testing
- QLC5513 IV infusion, QL1706, IV infusion, platinum, IV infusion
- Volunteers
- 290 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Myelodysplastic Syndrome
Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)
This is a multicenter, multinational, non-randomized, non-controlled open-label phase II trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to…
- Trial name
- NCT01062490
- Testing
- Treosulfan
- Where
- Finland
- Volunteers
- 45 people
- Sponsor
- medac GmbH
Bladder Cancer
A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)
This is a randomized, multicenter, two-arm, double-blind, placebo-controlled study of Qapzola in participants with low- to intermediate-risk non-muscle invasive bladder cancer (NMIBC), assessed according to the 2016 American…
- Trial name
- NCT03224182
- Testing
- Qapzola
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Advanced Solid Tumor
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
This is a phase I/II study to preliminarily explore of the safety, tolerability, pharmacokinetics, and efficacy of WJB001 combination therapy, consisting of three stages: Dose escalation (Phase Ia), dose extension (Phase Ib), and…
- Trial name
- NCT06953323
- Testing
- WJB001 Capsules+Paclitaxel/Paclitaxel-albumin, WJB001 Capsules+carboplatin/Nedaplatin, WJB001 Capsules+Paclitaxel+carboplatin
- Where
- 10 sites in China
- Volunteers
- 86 people
- Sponsor
- Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Advanced Solid Tumor
A Study of the ILB-3101 in Patients with Advanced Solid Tumors
ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06426680
- Testing
- ILB-3101
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Innolake Biopharm
Mesothelioma
A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma
Based on results from earlier clinical trials, Pemetrexed may have antitumor activity as a first-line agent in the treatment of mesothelioma.
- Trial name
- NCT00190762
- Testing
- Pemetrexed
- Where
- Canada
- Volunteers
- 240 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
A Study of Talazoparib in Patients With Advanced Solid Tumors
This study will evaluate the mass balance of talazoparib after a single dose of talazoparib.
- Trial name
- NCT03070548
- Testing
- Talazoparib
- Where
- Hungary
- Volunteers
- 6 people
- Sponsor
- Pfizer
Chronic Myeloid Leukemia
Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)
This study will assess the maximum tolerated dose of low dose interferon in conjunction with nilotinib in pretreated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia patients in chronic phase (CML-CP).
- Trial name
- NICOLI (NCT01220648)
- Testing
- Nilotinib, interferon-alfa
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
To assess efficacy and safety of oral TQ-B3101 administered to patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that confirmed ROS1 positive gene mutation.
- Trial name
- NCT03972189
- Testing
- TQ-B3101
- Where
- 22 sites in China
- Volunteers
- 111 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.